Western Europe

Digestive remedies has seen robust current value growth in 2023 due to a combination of two factors. Firstly, Belgians rediscovered the joy of taking holidays, more particularly outbound trips and local excursions. Until the end of 2021, it was…

Dietary supplements in the Netherlands presents a varied picture in terms of retail volume and value growth during the review period. Amidst the Coronavirus (COVID-19) pandemic, there was a surge in the retail sales of dietary supplements known to…

Sales of dietary supplements remained relatively stable throughout the review period and into 2023, despite the influence of the COVID-19 pandemic. Unlike vitamins, which surged in popularity during the early stages of the pandemic, dietary…

Dietary supplements is set to see strong growth in current value terms in 2023. One major driver of this performance is the dynamic growth being seen in probiotic supplements in 2023, which is set to see the second consecutive year of double-digit…

Healthier lifestyles and a focus on immune system support are the key drivers of dietary supplements sales in 2023. Concerns surrounding COVID-19 led more Irish consumers to start taking dietary supplements on a regular basis as a preventive measure…

Digestive health has recovered its status as a key growth driver in dietary supplements, with probiotics amongst the best performers in the Greek market. Demand was growing rapidly prior to the outbreak of COVID-19, but the pandemic led to growth…

The pandemic led to shifts in French consumer behaviour, including an increasing understanding of the importance of consistency to achieve overall wellbeing. Heightened health awareness around sickness prevention, and overall health and immunity have…

Dietary supplements are a sizeable product area in Denmark and received a significant boost from the COVID-19 pandemic as consumers sought to boost their immune systems and protect themselves against the virus. In 2023, dietary supplements is seeing…

Dietary supplements continues to see steady current value growth in 2023, in line with the performance seen in 2022. However, since the beginning of 2022, there has been an explosion in the price of ingredients (often imported) and energy costs and…

In general, dermatologicals was largely unaffected by the Coronavirus (COVID-19) pandemic. Most categories of dermatologicals continued to see retail volume growth in 2020, many of them at a similar rate to 2019. There are a number of underlying…

Dermatologicals continued to record positive value growth in current price terms over the course of 2023 as the essential nature of many of these products for those experiencing moderate skin health issues ensured that demand remained relatively…

Dermatologicals is seeing steady single-digit growth in current value terms in 2023. Two of the most important product areas, topical antifungals and vaginal antifungals, are both seeing moderate growth in 2023, although this is largely due to…

Dermatologicals is seeing solid current value growth in 2023, driven in part by higher retail prices. The category is benefiting from a return to normal daily lifestyles following the COVID-19 pandemic. Consumers’ skin is being more exposed to…

Dermatologicals has seen demand weaken in the post-pandemic period. While certain COVID-19 related habits, such as the use of hand sanitisers, remain relevant and people in Greece continue to use them much more than they did in the past, this is a…

Value growth for dermatologicals continues to slow in 2023 as local consumers prioritise the treatment of other health concerns. According to a study led by the French Society of Dermatology (SFD), one in three French citizen suffers from a skin…

Dermatologicals is expected to register an increase in current value sales in 2023, partly as a result of the energy crisis stemming from the war in Ukraine, which is pushing up retail prices.

Sales of dermatologicals strongly rely on consumers visiting pharmacies (the dominant distribution channel) as Belgians rarely go first to these stores specifically to purchase such products. Instead these are generally secondary purchases alongside…

Cough, cold, and allergy (hay fever) remedies is projected to continue to post retail current value growth in 2023, following a severe decline in 2020 due to the Coronavirus (COVID-19) pandemic. Having passed the 2019 pre-pandemic level in 2022, the…

Cough, cold and allergy (hay fever) remedies remains the largest OTC category in Norway, accounting for more than one-third of total OTC value sales in 2023. Despite the already relatively high penetration of these products, the category registered…

Cough/cold remedies are set to see high single-digit growth in current value terms in 2023, with sales likely to benefit from a high number of cases of cold and flu in the 2023/2024 season. Furthermore, value sales will likely also be boosted by unit…